These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36655383)

  • 1. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence.
    Ripabelli G; Salzo A; Tamburro M
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168947. PubMed ID: 36655383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence.
    Mungmunpuntipantip R; Wiwanitkit V
    Hum Vaccin Immunother; 2022 Dec; 18(7):2149015. PubMed ID: 36404633
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Results from an active pharmacovigilance study in central Italy.
    Ripabelli G; Sammarco ML; D'Amico A; De Dona R; Iafigliola M; Parente A; Samprati N; Santagata A; Adesso C; Natale A; Di Palma MA; Cannizzaro F; Romano R; Licianci A; Tamburro M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2126668. PubMed ID: 36315849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
    Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
    Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
    J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe cutaneous reaction to the messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) vaccine.
    Sapsford S; Wood B
    N Z Med J; 2022 Oct; 135(1564):72-76. PubMed ID: 36302245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
    Teo SP
    J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
    Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
    Novembre E; Tosca M; Caffarelli C; Calvani M; Cardinale F; Castagnoli R; Chiappini E; Cravidi C; Del Giudice MM; Duse M; Licari A; Manti S; Martelli A; Ricci G; Pingitore G; Marseglia GL
    Ital J Pediatr; 2022 May; 48(1):76. PubMed ID: 35578294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years.
    Lopez Bernal J; Andrews N; Gower C; Stowe J; Tessier E; Simmons R; Ramsay M
    Clin Infect Dis; 2024 Feb; 78(2):349-351. PubMed ID: 37758203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study.
    Chan EWW; Leung MTY; Lau LKW; Leung J; Lum D; Wong RS; Li X; Chui CSL; Wan EYF; Wong CKH; Chan EWY; Ip P; Wong ICK; Lai FTT
    Int J Infect Dis; 2022 Mar; 116():47-50. PubMed ID: 34965462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic events following the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) in Aotearoa New Zealand: A self-controlled case series study.
    Walton M; Tomkies R; Teunissen T; Lumley T; Hanlon T
    Thromb Res; 2023 Feb; 222():102-108. PubMed ID: 36634464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Ludwikowska KM; Popiel A; Matkowska-Kocjan A; Olbromski MJ; Biela M; Wójcik M; Szenborn F; Wielgos K; Pielka-Markiewicz E; Zaryczański J; Kursa MB; Szenborn L
    Vaccine; 2023 Mar; 41(13):2289-2299. PubMed ID: 36870876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
    Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
    Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.
    Woodworth KR; Moulia D; Collins JP; Hadler SC; Jones JM; Reddy SC; Chamberland M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Mbaeyi S; Dooling K; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(45):1579-1583. PubMed ID: 34758012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.